Enlivex Therapeutics

About

Funding history · 9 rounds · — total

Headcount over time

Q&A

What is Enlivex Therapeutics' primary focus?

Enlivex Therapeutics is a clinical-stage biopharmaceutical company focused on developing immunotherapies for inflammatory conditions, particularly through macrophage reprogramming. They are also involved in a prediction markets treasury strategy.

What is Allocetra and what is its purpose?

Allocetra is Enlivex Therapeutics' universal off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. It is being developed for the treatment of inflammatory diseases such as osteoarthritis, sepsis, and solid tumors.

When did Enlivex Therapeutics become a public company?

Enlivex Therapeutics became public on NASDAQ in March 2019 and on TASE in July 2019.

What was the most recent funding round for Enlivex Therapeutics?

Enlivex Therapeutics completed a PIPE funding round in November 2025, raising $212,000,000.

What was the total amount raised by Enlivex Therapeutics to date?

According to startupim data, Enlivex Therapeutics has raised a total of $452,200,000 USD.

What is the current employee count for Enlivex Therapeutics?

Enlivex Therapeutics currently has 34 employees, falling within the 11-50 employee bucket.

Has Enlivex Therapeutics received regulatory authorization for clinical trials in knee osteoarthritis?

Yes, in February 2024, Enlivex Therapeutics received regulatory authorization from Israel’s Health Ministry for the initiation of a Phase 1/2 trial evaluating Allocetra in patients with knee osteoarthritis.

What is the latest development regarding Allocetra in knee osteoarthritis trials?

In March 2025, Enlivex announced positive interim data, demonstrating a statistically significant 47.0% durable and persistent pain reduction at six months in patients with moderate to severe knee osteoarthritis.

Has Enlivex Therapeutics expanded its clinical trials for Allocetra internationally?

Yes, in January 2023, Enlivex Therapeutics received authorizations from French and Belgian regulatory agencies to expand its Phase II Sepsis clinical trial into France and Belgium.

What is Enlivex Therapeutics' current market capitalization?

Enlivex Therapeutics has a market capitalization of $174,225,098 USD.

Team · 1

Dror Mevorach

Founder · Founder

Sectors & technology

Highlights

Tags